ClinicalTrials.gg
Not yet recruitingNCT07950267REDUCEUpdated Nov 20, 2026

Real-world Evidence of Inebilizumab in IgG4-RD

An observational study in IgG4-Related Diseases, sponsored by Peking Union Medical College Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Peking Union Medical College Hospital · Observational

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 15 studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital — 7 open to participants now, 7 under way, 1 of them phase 3. Immunoglobulin G4-Related Disease · Peking Union Medical College Hospital.

Started
2027
the only one that year
Observational
4 of 15
3 open now
Registered
15th of 15
by date

Among the 15 studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital, this one is the only one that started in 2027, is one of 4 observational ones, and was the 15th registered.

Immunoglobulin G4-Related Disease

73 studies on the registry are indexed under Immunoglobulin G4-Related Disease; 39 are open to participants now.

Browse Immunoglobulin G4-Related Disease studies →

Open to participants now

7 of the 15 studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 27 Immunoglobulin G4-Related Disease studies recruiting now, 11 (41%) set no upper age limit and 13 (48%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital, or all of them as a file.
02

Study summary

The goal of this observational study is to observe the efficacy and safety of inebilizumab in the treatment of IgG4-related disease. The main question it aims to answer the optimal steroid-sparing regimen for patients with IgG4-RD in clinical practice.

This study will enroll all patients with IgG4-RD treated with inebilizumab. Enrolled patients will receive different treatment regimens according to disease severity and whether they are taking other immunosuppressive agents.

Read the detailed description

All enrolled patients will be categorized into four subtypes based on disease severity and concomitant use of other immunosuppressive agents:

Group1 Treatment-naive active disease treated with inebilizumab monotherapy group: treatment-naive patients or patients with post-discontinuation relapse, in whom the investigator assesses that the disease is suitable for inebilizumab monotherapy; Group2 Treatment-naive active disease treated with short-course corticosteroids plus inebilizumab group: treatment-naive patients or patients with post-discontinuation relapse, in whom the investigator assesses that short-course corticosteroids are required in combination; Group3 Stable disease continued-treatment group: patients with stable disease control on long-term corticosteroids or corticosteroids plus conventional immunosuppressants, who are at high risk of relapse after discontinuation and are willing to switch to a steroid-free inebilizumab treatment regimen; Group4 Relapsed/refractory patient group: patients who experience relapse while receiving corticosteroids or corticosteroids combined with immunosuppressants.

03

Conditions studied

  • IgG4-Related Diseases

Keywords

  • steroid-sparing
  • IgG4-related disease
  • inebilizumab
  • B-cell depletion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All IgG4-related disease patients treated with inebilizumab.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥18 years old;
  2. Meet the 2019 ACR/EULAR classification criteria or the 2020 Japanese diagnostic criteria for IgG4-RD;
  3. Plan to receive treatment with inebilizumab;
  4. Signed form.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating female patients;
  2. Participation in other interventional studies within 30 days prior to screening, or exposure to products within 5 half-lives before enrollment, or planned participation in other interventional studies during the trial period;
  3. Patients with to inebilizumab treatment;
  4. Any other conditions deemed inappropriate for enrollment by the investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Patients with IgG4-RD treated with inebilizumab

    Patients with IgG4-RD receiving inebilizumab in the real-world setting

06

What researchers measure

Primary outcomes

  1. Relapse rate

    Flare of IgG4-RD is defined as the reappearance of previous symptoms or signs of IgG4-RD or the appearance of new symptoms or signs attributed to IgG4-RD, based on clinical assessment, laboratory tests, and/or imaging, and reflected by an increase in the IgG4-RD Responder Index

    Time frame: One year after inebilizumab treatment

Secondary outcomes

  1. Proportion of subjects achieving flare-free and treatment-free complete remission

    Flare-free and treatment-free complete remission was defined as the absence of any disease flare, no glucocorticoid for flare, and the absence of disease activity

    Time frame: Three Months, six months and twelve months after inebilizumab treatment

  2. Proportion of subjects achieving flare-free and glucocorticoid-free complete remission

    Flare-free and glucocorticoid-free complete remission was defined as the absence of any disease flare, no glucocorticoid for flare, and the absence of disease activity

    Time frame: Three Months, six months and twelve months after inebilizumab treatment

  3. Remission rate after inebilizumab treatment

    The investigator determined that there was no evidence of disease activity at the visit

    Time frame: Six months and twelve months after inebilizumab treatment

  4. IgG4-RD Responder Index (IgG4-RD RI) after inebilizumab treatment

    Measured by IgG4-RD Responder Index

    Time frame: Three Months, six months and twelve months after inebilizumab treatment

  5. IgG4-RD Damage Index (IgG4-RD DI) after inebilizumab treatment

    Measured by IgG4-RD Damage Index

    Time frame: Three Months, six months and twelve months after inebilizumab treatment

  6. Changes in serum IgG4 levels from baseline after inebilizumab treatment

    Laboratory markers

    Time frame: Three Months, six months and twelve months after inebilizumab treatment

  7. Changes in serum B-cell levels from baseline after inebilizumab treatment

    Laboratory markers

    Time frame: Three Months, six months and twelve months after inebilizumab treatment

  8. Total amount of glucocorticoids during inebilizumab administration

    Total amount of glucocorticoids calculated as the cumulative glucocorticoid dose (in milligrams) taken for the purpose of IgG4-RD disease control. This measure accounted for all glucocorticoids treatments administered to participants to manage disease activity throughout the study period.

    Time frame: One year after inebilizumab treatment

  9. Improvement in patients' quality of life during inebilizumab administration

    Quality of life measured by the EQ-5D-5L questionnaire

    Time frame: One year after inebilizumab treatment

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — IPD will not be shared with other researchers. Data may be made available to regulatory authorities, trial monitors, auditors, and ethics committees as required for trial oversight, monitoring, audit, and verification.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Dec 2028, 23 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2026
First posted
Nov 20, 2026
StartEst.
Jan 2027
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2029
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07950267
Responsible party
Wen Zhang (Professor; Vice director of rheumatology department, Peking Union Medical College Hospital) — Principal investigator
First posted
Nov 20, 2026
Start date
Jan 2027 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 20, 2026

Study contacts

Linyi Peng
Contact
drpenglinyi@163.com
+86-10-69155004

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion